The University of Chicago Header Logo

Connection

Akash Patnaik to Humans

Back to Details
This is a "connection" page, showing publications Akash Patnaik has written about Humans.
Akash Patnaik
Connection Strength
0.256
Humans
  1. Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. Clin Cancer Res. 2023 12 01; 29(23):4930-4940.
    View in: PubMed
    Score: 0.029
  2. BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade. Mol Cancer Ther. 2023 06 01; 22(6):751-764.
    View in: PubMed
    Score: 0.028
  3. Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2023 03; 7:e2200483.
    View in: PubMed
    Score: 0.028
  4. Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors. Mol Cancer Ther. 2021 02; 20(2):438-449.
    View in: PubMed
    Score: 0.024
  5. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy. Urol Oncol. 2019 08; 37(8):535-542.
    View in: PubMed
    Score: 0.021
  6. Mouse Models for Cancer Immunotherapy Research. Cancer Discov. 2018 11; 8(11):1358-1365.
    View in: PubMed
    Score: 0.020
  7. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov. 2017 07; 7(7):750-765.
    View in: PubMed
    Score: 0.018
  8. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
    View in: PubMed
    Score: 0.007
  9. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 09; 84(3):321-330.
    View in: PubMed
    Score: 0.007
  10. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer. Clin Cancer Res. 2023 05 15; 29(10):1952-1968.
    View in: PubMed
    Score: 0.007
  11. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. 2023 03; 83(3):200-209.
    View in: PubMed
    Score: 0.007
  12. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clin Cancer Res. 2021 12 15; 27(24):6677-6686.
    View in: PubMed
    Score: 0.006
  13. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncol Pract. 2020 12; 16(12):811-819.
    View in: PubMed
    Score: 0.006
  14. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020 10 12; 38(4):489-499.e3.
    View in: PubMed
    Score: 0.006
  15. Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2. Mol Cancer Ther. 2020 10; 19(10):2023-2033.
    View in: PubMed
    Score: 0.006
  16. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 11 10; 38(32):3763-3772.
    View in: PubMed
    Score: 0.006
  17. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Clin Cancer Res. 2020 06 01; 26(11):2487-2496.
    View in: PubMed
    Score: 0.006
  18. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 08; 17(4):275-282.e1.
    View in: PubMed
    Score: 0.005
  19. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82.
    View in: PubMed
    Score: 0.004
  20. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014 Aug; 4(8):896-904.
    View in: PubMed
    Score: 0.004
  21. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Jul; 45(7):747-55.
    View in: PubMed
    Score: 0.004
  22. The APL paradigm and the "co-clinical trial" project. Cancer Discov. 2011 Jul; 1(2):108-16.
    View in: PubMed
    Score: 0.003
  23. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res. 2010 Jul 01; 16(13):3322-8.
    View in: PubMed
    Score: 0.003
  24. PI3K enters beta-testing. Cell Metab. 2008 Sep; 8(3):179-81.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.